Innovators from Global Biopharma Companies Discuss Consumer & Physician E-marketing Trends

Manhattan ResearchIn recent years European healthcare consumers and physicians have steadily increased their use of the Internet for treatment and product decisions. According to healthcare and pharmaceutical market research company's Manhattan Research's Cybercitizen Health™ Europe v8.0 study and strategy advisory service, over 150 million adults in countries across Europe used online channels to access health information in 2008.

In light of these trends, it's become necessary for biopharmaceutical companies to explore digital strategies in order to connect with target consumer and physician audiences at both a European and global level - however, they face a myriad of challenges in terms of regulations, process, and internal understanding.

To encourage innovation and knowledge-sharing across the industry, Manhattan Research releases its 2008 European Opinion Leader Roundtable report - a collection of opinions and best practices on key e-marketing and sales topics from innovators at AstraZeneca, UCB Pharma, Shire Pharmaceuticals, and Across Health. The virtual discussion is led by Manhattan Research President Mark Bard.

"Biopharma companies in Europe - and globally as well - can no longer afford to ignore 'e' channels as viable and cost-effective ways to reach consumer and physician groups," said Mr. Bard, "The key opinion leaders in this roundtable are catalysts for digital innovation within their respective organizations and offer valuable lessons learned and best practices for marketing and sales teams."

European Opinion Leader Roundtable Summary

Moderator:
Mark Bard, Manhattan Research

Opinion Leaders:
John Fish, AstraZeneca
Jean-Pierre Henskens, UCB Pharma
Gene Miller, Shire Pharmaceuticals
Fonny Schenck, Across Health

Topics:

  • Web-Empowered Healthcare Consumers
  • Facing Regulatory Challenges
  • Patient Compliance & Digital Strategy
  • Search Engine Marketing
  • Physicians & Closed Loop Marketing
  • Integration & Measurement
  • E-marketing Lessons Learned

The roundtable report is available to download on the Manhattan Research website. Please visit: http://www.manhattanresearch.com/research/roundtables/european-roundtable-2008.aspx.

Manhattan Research European Study & Strategic Advisory Service Products
Manhattan Research offers two European market research study & strategic advisory services for the healthcare and biopharmaceutical companies.

Cybercitizen Health™ Europe is focused on how European consumers use new media and technology for health information and its impact on treatment and product decisions. The latest study was conducted in Q3 2008 among 4,079 consumers in the United Kingdom, Germany, Spain, Italy, France, Belgium, Sweden, the Netherlands, Poland, and Portugal. Cybercitizen Health™ Europe identifies and analyses the behaviour, attitudes, and demographics of the consumer population who use technology and the Internet for health purposes, as well as further segmenting the population by therapeutic area, technology utilisation, and motivation. For more information, visit http://www.manhattanresearch.com/products/consumer/ccheu.aspx

Taking the Pulse® Europe is focused on how physicians across Europe use new media and technology for professional purposes. The next study will be available at the end of Q4 2008. Last year's study was fielded among 1,000 physicians from the United Kingdom, Germany, Spain, Italy, and France. Taking the Pulse® Europe provides pharmaceutical and healthcare companies with key data and insight about the evolving nature of physician channel mix, media and technology usage, and healthcare information with the goal of helping companies understand how physicians across Europe access health information. For more information, visit http://www.manhattanresearch.com/products/physician/EUphysicians.aspx

In addition to the core data, subscribing clients have access to the Manhattan Research analyst team and the ability to request country-specific therapeutic and specialist segmentations.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...